E986 CMAJ| AUGUST 20, 2018| VolUMe 190| ISSUe 33 patient's quality of life. The most
common adverse effects include vasomotor symptoms, such as hot flashes with nausea …

Background Androgen deprivation therapy has some clinical activity in selected salivary
gland cancer histotypes, with androgen receptor expression. Methods We retrospectively …

Background There is no standard first-line chemotherapy for recurrent/metastatic (RM) or
unresectable locally advanced (LA) salivary gland carcinoma (SGC). Patients and methods …

Objectives: There is a lack of effective therapy for recurrent or metastatic salivary gland
carcinoma. Androgen deprivation therapy has demonstrated efficacy in cases of salivary …

PURPOSE The androgen receptor (AR) is expressed (+) in a subset of salivary gland
cancers (SGCs). This phase II trial evaluated the efficacy of the antiandrogen enzalutamide …

Background A phase II trial of combined androgen blockade (CAB) in patients with
advanced androgen receptor (AR)–positive salivary gland carcinoma (SGC) showed 40% of …

Background: SGCs are rare and heterogenous tumors (< 1% of all malignancies in Europe).
Among more than 20 histotypes, only salivary duct carcinoma (SDC) and adenocarcinoma …

e18091 Background: Salivary gland cancers (SGC) are rare malignancies with no standard
systemic therapy available for patients with recurrent or metastatic disease. Androgen …

Androgen receptor (AR) is a steroid hormone receptor activated by circulating androgens
(Fig 1). Engagement of AR with its cognate ligands testosterone and dihydrotestosterone …

METHODS This was a single-institution phase II trial. A two-stage Simon's design was
applied. The primary end point was confirmed objective response rate. Secondary end …